Llwytho...
Core binding factor acute myelogenous leukemia-2021 treatment algorithm
Core binding factor acute myelogenous leukemia (CBF-AML), characterized by the presence of either t(8;21) (q22;q22) or inv(16) (p13q22)/t(16;16), is considered good-risk AML in the context of cytarabine based intensive chemotherapy. Still, outcome can be improved significantly through the effective...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Blood Cancer J |
|---|---|
| Prif Awduron: | , |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
Nature Publishing Group UK
2021
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8209225/ https://ncbi.nlm.nih.gov/pubmed/34135311 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-021-00503-6 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|